HVC
Healthcare Value Capital Portfolio holdings
AUM
$38.5M
1-Year Return
22.29%
This Quarter Return
+82.17%
1 Year Return
+22.29%
3 Year Return
+31.09%
5 Year Return
+125.72%
10 Year Return
–
AUM
$41.1M
AUM Growth
+$6.4M
(+18%)
Cap. Flow
-$925K
Cap. Flow
% of AUM
-2.25%
Top 10 Holdings %
Top 10 Hldgs %
99.92%
Holding
12
New
–
Increased
2
Reduced
2
Closed
–
Top Buys
| 1 |
ATRS
Antares Pharma, Inc.
ATRS
|
+$504K |
| 2 |
TYME
Tyme Technologies, Inc. Common Stock
TYME
|
+$278K |
Top Sells
| 1 |
NVLN
Novelion Therapeutics Inc. Common Shares
NVLN
|
+$894K |
| 2 |
AMRN
Amarin Corp
AMRN
|
+$814K |
Sector Composition
| 1 | Healthcare | 94.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Gilead Sciences
GILD
$142B
| $7.72M | 18.67% |
100,000
| – | – |
|
|
AMRN
2
Amarin Corp
AMRN
$310M
| $7.32M | 17.71% |
22,500
-2,500
| -10% | -$814K |
|
|
TYME
3
DELISTED
Tyme Technologies, Inc. Common Stock
TYME
| $6.05M | 14.62% |
2,175,000
+100,000
| +5% | +$278K |
|
4
GSK
GSK
$82.2B
| $4.02M | 9.71% |
80,000
| – | – |
|
|
AGN
5
DELISTED
Allergan plc
AGN
| $3.81M | 9.21% |
20,000
| – | – |
|
6
Standard BioTools
LAB
$493M
| $3.37M | 8.15% |
450,000
| – | – |
|
|
NVLN
7
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
| $2.99M | 7.24% |
1,011,487
-301,900
| -23% | -$894K |
|
8
Viking Therapeutics
VKTX
$2.79B
| $2.61M | 6.32% |
150,000
| – | – |
|
9
ProShares UltraShort NASDAQ Biotechnology
BIS
$2.37M
| $2.35M | 5.67% |
37,500
| – | – |
|
|
ATRS
10
DELISTED
Antares Pharma, Inc.
ATRS
| $840K | 2.03% |
250,000
+150,000
| +150% | +$504K |
|
|
SEEL
11
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
| $31K | 0.08% |
1
| – | – |
|
|
LCI
12
DELISTED
Lannett Company, Inc.
LCI
| – | – |
0
| – | – |
|